Yong‐Chen Lu
High Impact
Assistant Professor (Tenure Track)
faculty
Pathology, College of Medicine
28 h-index
90 pubs
12,407 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Yong‐Chen Lu's research focuses on understanding and manipulating T-cell responses in the context of cancer immunotherapy. His work investigates the molecular signatures of T cells that recognize tumor-specific antigens, known as neoantigens. Lu has published research on the direct identification of neoantigen-specific T-cell receptors (TCRs) from tumor specimens using high-throughput single-cell sequencing, a technique that is crucial for studying T-cell biology and developing cancer therapies.
His group studies adoptive cellular therapy, including the use of autologous tumor-infiltrating lymphocytes and TCR-engineered T cells. Recent publications explore the potential of liquid biopsies in hepatocellular carcinoma for immunotherapy and the identification of neoantigen-reactive T lymphocytes in various human cancers, such as glioblastoma. Lu also investigates the role of specific molecules, such as TREM-2, in mediating immune responses that can impact chronic diseases.
Lu leads a research group and has collaborated with researchers at the University of Arkansas for Medical Sciences, including Charles M. Quick, Mayumi Nakagawa, Hannah Coleman, and Takeo Shibata, with whom he shares multiple publications. His work is recognized with a high h-index of 28 and over 12,000 citations.
Metrics
- h-index: 28
- Publications: 90
- Citations: 12,407
Selected Publications
-
Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
Isolation of mitochondrial mutation-specific T cell receptors (2025)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation (2025)
-
376 Inhibition of GSK3β-mediated 53BP1 T334 phosphorylation in T cells enhances infiltration and cytotoxicity against head and neck squamous cell carcinoma (2024)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
Deciphering CD4<sup>+</sup> T cell‐mediated responses against cancer (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
Grants & Funding
- Developing T cell-based immunotherapy targeting breast cancer antigen FBXO39 ABCRP Principal Investigator
- Developing CD4 T cell-based immunotherapy for breast cancer ABCRP Principal Investigator
- Defining tumor infiltrating B cells and their role in the modulation of TIL immunotherapy The Mark Foundation for Cancer Research - Pass Through: H Lee Moffitt Cancer Center & Research Institute Co-Investigator
- A pilot study of developing T cell-based cancer immunotherapies for African American and Hispanic populations TRI Principal Investigator
Collaboration Network
Top Collaborators
Steven A. Rosenberg
24 shared publications
- Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
- Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
- 651 Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction
- Abstract 127: Single cell mapping of tumor infiltrating lymphocytes enables neoantigen-reactive T cell identification in metastatic human cancer
- Data from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy
Showing 5 of 24 shared publications
Maria R. Parkhurst
23 shared publications
- Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers
- Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- 651 Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction
- Abstract 127: Single cell mapping of tumor infiltrating lymphocytes enables neoantigen-reactive T cell identification in metastatic human cancer
- Adoptive cell therapy targeting common p53 neoantigens in human solid cancers
Showing 5 of 23 shared publications
Jared J. Gartner
23 shared publications
- Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers
- Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
- Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
- Adoptive cell therapy targeting common p53 neoantigens in human solid cancers
Showing 5 of 23 shared publications
Biman C. Paria
22 shared publications
- Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers
- Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
- Adoptive cell therapy targeting common p53 neoantigens in human solid cancers
- Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Showing 5 of 22 shared publications
Parisa Malekzadeh
20 shared publications
- Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Adoptive cell therapy targeting common p53 neoantigens in human solid cancers
- Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Showing 5 of 20 shared publications
Drew C. Deniger
20 shared publications
- Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Adoptive cell therapy targeting common p53 neoantigens in human solid cancers
- Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Showing 5 of 20 shared publications
Satyajit Ray
20 shared publications
- Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Adoptive cell therapy targeting common p53 neoantigens in human solid cancers
- Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Showing 5 of 20 shared publications
Paul Robbins
16 shared publications
- Data from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Table 3 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Showing 5 of 16 shared publications
Anna Pasetto
University of Oslo (NO)
15 shared publications
- Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
- Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy
- Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Showing 5 of 15 shared publications
Todd D. Prickett
14 shared publications
- Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
- Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Showing 5 of 14 shared publications
Scott Kivitz
13 shared publications
- Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Showing 5 of 13 shared publications
Frank J. Lowery
12 shared publications
- Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers
- Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
- Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
- 651 Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction
- Abstract 127: Single cell mapping of tumor infiltrating lymphocytes enables neoantigen-reactive T cell identification in metastatic human cancer
Showing 5 of 12 shared publications
Winifred Lo
12 shared publications
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Table 3 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Showing 5 of 12 shared publications
Thomas E. Shelton
12 shared publications
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Table 3 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Showing 5 of 12 shared publications
Isaac Kriley
12 shared publications
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Figure 5 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- Supplementary Table 3 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Showing 5 of 12 shared publications
Similar Researchers
Based on overlapping research topics
Amir Mahari
University of Arkansas at Fayetteville
Cancer Immunotherapy and Biomarkers
Immune Cell Function and Interaction
Cancer Cells and Metastasis
Yong-Chen Lu
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Immune Cell Function and Interaction
T-cell and B-cell Immunology
Latambria Hampton
University of Arkansas for Medical Sciences
Immune Cell Function and Interaction
T-cell and B-cell Immunology
Molecular Biology Techniques and Applications
Katie R. Ryan
University of Arkansas for Medical Sciences
Molecular Biology Techniques and Applications
Cancer Cells and Metastasis
Receptor Mechanisms and Signaling
Madison McClanahan
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Immune Cell Function and Interaction
Cancer Cells and Metastasis
B.R. Hicks
University of Arkansas for Medical Sciences
T-cell and B-cell Immunology
Molecular Biology Techniques and Applications
Receptor Mechanisms and Signaling